EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtFallberichtOpen Access · CC BY 4.0

The Long Journey towards Personalized Targeted Therapy in Poorly Differentiated Thyroid Carcinoma (PDTC): A Case Report and Systematic Review

Odysseas Violetis, Panagiota Konstantakou, Ariadni Spyroglou iD, Antonios Xydakis iD, Panagiotis B Kekis, Sofia Tseleni, Denise Kolomodi, Manousos Konstadoulakis, George Mastorakos iD, Maria Theochari, Javier Aller, Krystallenia I Alexandraki iD

Journal of Personalized Medicine · 18.06.2024 · 14 (6) · 654

DOI: 10.3390/jpm14060654 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Personalized Medicine, online erschienen am 18.06.2024. Verfasst von Odysseas Violetis und 11 weiteren Autor:innen. Beteiligte Einrichtung: 2nd Department of Surgery, Aretaieio Athens Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Poorly differentiated thyroid carcinoma (PDTC) has an intermediate prognosis between indolent well-differentiated thyroid carcinoma (TC) and anaplastic carcinoma. Herein, we present a case report with a PDTC component, along with a systematic review of the literature. Case Report: We report a case of a 45-year-old man diagnosed with a PDTC component, along with hobnail and tall-cell variant features positive for BRAFV600E mutation, after a total thyroidectomy and neck dissection. Radioactive iodine (RAI)-131 therapy was applied, but an early recurrence led to complementary surgeries. The anti-Tg rise, the presence of new lymph nodes, and the negative whole-bodyradioiodine scan were suggestive of a radioiodine-resistant tumor. Lenvatinib, sorafenib, dabrafenib/trametinib, cabozantinib and radiotherapy were all administered, controlling the tumor for a period of time before the patient ultimately died post-COVID infection. Systematic Review: We searched PubMed, Scopus, and WebofScience to identify studies reporting clinicopathological characteristics, molecular marker expression, and management of non-anaplastic TC with any proportion of PDTC in adult patients. Of the 2007 records retrieved, 82were included in our review (PROSPERO-ID545847).

Conclusions

Our case, together with the systematic review, imply that a combination of molecular-targetedtreatments may be safe and effective in patients with RAI-resistantBRAF-mutated advanced PDTC when surgery has failed to control tumor progression.

Schlagwörter

Stichwörter der Autor:innen

hobnail thyroid carcinomamolecular-targeted therapy in thyroid cancerpoorly differentiated thyroid carcinomatall-cell thyroid carcinoma

Autor:innen und Institutionen

  • 2nd Department of Surgery, Aretaieio Athens Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
  • Endocrine Surgery Department, Athens Medical Center, 15125 Athens, Greece.
  • Department of Pathology, Medical School, University of Athens, 11527 Athens, Greece.
  • European Neuroendocrine Tumor Society (ENETS) Center of Excellence, Ekpa-Laiko Center, 11527 Athens, Greece.
  • IATROPOLIS Private Medical Center, 11521 Athens, Greece.
  • Department of Oncology, Ippokrateio Athens General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.

ORCID-Profile: Ariadni Spyroglou, Antonios Xydakis, George Mastorakos, Krystallenia I Alexandraki

Zitieren

APA

Violetis, O., Konstantakou, P., Spyroglou, A., Xydakis, A., Kekis, P. B., Tseleni, S., Kolomodi, D., Konstadoulakis, M., Mastorakos, G., Theochari, M., Aller, J., & Alexandraki, K. I. (2024). The Long Journey towards Personalized Targeted Therapy in Poorly Differentiated Thyroid Carcinoma (PDTC): A Case Report and Systematic Review. Journal of Personalized Medicine, 14(6), 654. https://doi.org/10.3390/jpm14060654

Vancouver

Violetis O, Konstantakou P, Spyroglou A, Xydakis A, Kekis PB, Tseleni S, et al. The Long Journey towards Personalized Targeted Therapy in Poorly Differentiated Thyroid Carcinoma (PDTC): A Case Report and Systematic Review. Journal of Personalized Medicine. 2024;14(6):654. doi:10.3390/jpm14060654

BibTeX
@article{Violetis2024,
  author = {Violetis, Odysseas and Konstantakou, Panagiota and Spyroglou, Ariadni and Xydakis, Antonios and Kekis, Panagiotis B and Tseleni, Sofia and Kolomodi, Denise and Konstadoulakis, Manousos and Mastorakos, George and Theochari, Maria and Aller, Javier and Alexandraki, Krystallenia I},
  title = {The Long Journey towards Personalized Targeted Therapy in Poorly Differentiated Thyroid Carcinoma (PDTC): A Case Report and Systematic Review},
  journal = {Journal of Personalized Medicine},
  year = {2024},
  volume = {14},
  number = {6},
  pages = {654},
  doi = {10.3390/jpm14060654}
}
Kostenlos starten →